Application of metabolomics to the study of irritable bowel syndrome.
irritable bowel syndrome
mass spectometry
metabolites
metabolomics
microbiota
nuclear magnetic resonance
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
07
04
2020
revised:
24
04
2020
accepted:
25
04
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
24
6
2021
Statut:
ppublish
Résumé
The pathophysiology of irritable bowel syndrome and the detection of biomarkers of specific mechanisms and/or predictors of therapeutic response remain elusive. This roadblock reflects, in large part, the complexity and heterogeneity of the disorder. Recently, there has been growing evidence of a dietary and/or microbiome interaction with the host that may trigger symptoms in a subset of patients. While a number of techniques are available to examine these potential interactions, "omic" approaches such as metabolomics are becoming more widely used. Metabolomics measures hundreds and potentially thousands of known and unknown small molecule chemicals (metabolites) to provide a unique look into mechanisms that underlie symptom generation and potential predictors of therapeutic response. In this issue of the journal, Lee et al use nuclear magnetic resonance (NMR) to demonstrate the value of this approach to study IBS. This review examines the use of metabolomics to better understand IBS, focusing on what has been learned to date, practical and technical considerations, its potential for future research and how the study by Lee et al have contributed to these concepts.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13884Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262-1279.e2.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.e4.
Spiegel BMR, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848-858.
Crişan I-M, Dumitraşcu DL. Irritable bowel syndrome: peripheral mechanisms and therapeutic implications. Clujul Med. 2014;87:73-79.
Linsalata M, Riezzo G, D'Attoma B, Clemente C, Orlando A, Russo F. Noninvasive biomarkers of gut barrier function identify two subtypes of patients suffering from diarrhoea predominant-IBS: a case-control study. BMC Gastroenterol. 2018;18:167.
Lee JS, Kim S-Y, Chun YS, et al. Characteristics of fecal metabolic profiles in patients with irritable bowel syndrome with predominant diarrhea investigated using 1H-NMR coupled with multivariate statistical analysis. Neurogastroenterol Motil 2020;e13830.
Kell DB. Metabolomics and systems biology: making sense of the soup. Curr Opin Microbiol. 2004;7:296-307.
Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 2018;46:D608-d617.
Dunn WB, Lin W, Broadhurst D, et al. Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics. 2015;11:9-26.
Holmes E, Loo RL, Stamler J, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453:396-400.
Moore SC, Matthews CE, Sampson JN, et al. Human metabolic correlates of body mass index. Metabolomics. 2014;10:259-269.
Elliott P, Posma JM, Chan Q, et al. Urinary metabolic signatures of human adiposity. Sci Transl Med. 2015;7:285ra262.
Yu Z, Zhai G, Singmann P, et al. Human serum metabolic profiles are age dependent. Aging Cell. 2012;11:960-967.
van Valkengoed IGM, Argmann C, Ghauharali-van der Vlugt K, et al. Ethnic differences in metabolite signatures and type 2 diabetes: a nested case-control analysis among people of South Asian, African and European origin. Nutrition Diab. 2017;7:300.
Stella C, Beckwith-Hall B, Cloarec O, et al. Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res. 2006;5:2780-2788.
Guertin KA, Moore SC, Sampson JN, et al. Metabolomics in nutritional epidemiology: identifying metabolites associated with diet and quantifying their potential to uncover diet-disease relations in populations. Am J Clin Nutr. 2014;100:208-217.
O'Sullivan A, Gibney MJ, Brennan L. Dietary intake patterns are reflected in metabolomic profiles: potential role in dietary assessment studies. Am J Clin Nutr. 2011;93:314-321.
Böhn L, Störsrud S, Liljebo T, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399-1407.e2.
McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017;66:1241-1251.
Wishart DS. Metabolomics: applications to food science and nutrition research. Trends Food Sci Technol. 2008;19:482-493.
Rajilic-Stojanovic M, Jonkers DM, Salonen A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol. 2015;110:278-287.
Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology. 1997;112:1714-1743.
Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77:1033-1079.
Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693-702.
Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79:727-747.
Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol. 2009;9:6-6.
Yamamoto M, Pinto-Sanchez MI, Bercik P, Britz-McKibbin P. Metabolomics reveals elevated urinary excretion of collagen degradation and epithelial cell turnover products in irritable bowel syndrome patients. Metabolomics. 2019;15:82.
Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted Metabolomics Strategies-Challenges and Emerging Directions. J Am Soc Mass Spectrom. 2016;27:1897-1905.
Pedersen SM, Nielsen NC, Andersen HJ, et al. The serum metabolite response to diet intervention with probiotic acidified milk in irritable bowel syndrome patients is indistinguishable from that of non-probiotic acidified milk by 1H NMR-based metabonomic analysis. Nutrients. 2010;2:1141-1155.
Le Gall G, Noor SO, Ridgway K, et al. Metabolomics of fecal extracts detects altered metabolic activity of gut microbiota in ulcerative colitis and irritable bowel syndrome. J Proteome Res. 2011;10:4208-4218.
Hong Y-S, Hong KS, Park M-H, et al. Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome. J Clin Gastroenterol. 2011;45:415-425.
Shankar V, Homer D, Rigsbee L, et al. The networks of human gut microbe-metabolite associations are different between health and irritable bowel syndrome. ISME j. 2015;9:1899-1903.
Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes. 2016;7:397-413.
Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153:448-459.e448.
Noorbakhsh H, Yavarmanesh M, Mortazavi SA, Adibi P, Moazzami AA. Metabolomics analysis revealed metabolic changes in patients with diarrhea-predominant irritable bowel syndrome and metabolic responses to a synbiotic yogurt intervention. Eur J Nutr. 2018;58(8):3109-3119.
Solakivi T, Kaukinen K, Kunnas T, Lehtimaki T, Maki M, Nikkari ST. Serum fatty acid profile in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2011;46:299-303.
Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol. 2011;60:817-827.
Ahmed I, Greenwood R, Costello Bde L, Ratcliffe NM, Probert CS. An investigation of fecal volatile organic metabolites in irritable bowel syndrome. PLoS ONE. 2013;8:e58204.
Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. Inflamm Bowel Dis. 2013;19:2069-2078.
Baranska A, Mujagic Z, Smolinska A, et al. Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach. Aliment Pharmacol Ther. 2016;44:45-56.
Gervasoni J, Schiattarella A, Giorgio V, et al. Validation of an LC-MS/MS method for urinary lactulose and mannitol quantification: results in patients with irritable bowel syndrome. Dis Markers. 2016;2016:5340386.
Mujagic Z, Jonkers DMAE, Ludidi S, et al. Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil. 2017;29:e13137.
Yu LM, Zhao KJ, Wang SS, Wang X, Lu B. Gas chromatography/mass spectrometry based metabolomic study in a murine model of irritable bowel syndrome. World J Gastroenterol. 2018;24:894-904.
Keshteli AH, Madsen KL, Mandal R, et al. Comparison of the metabolomic profiles of irritable bowel syndrome patients with ulcerative colitis patients and healthy controls: new insights into pathophysiology and potential biomarkers. Aliment Pharmacol Ther. 2019;49:723-732.
Fraser K, Young W, McNabb W, Gearry RB, Roy N. Su1576 - Metabolomic profiling of subjects with functional gastrointestinal disorders: a case/control study in New Zealand reveals significant perturbations in plasma lipid and metabolite levels. Gastroenterology. 2019;156:S-569-S-570.
Liu S, Si C, Yu Y, et al. Multi-omics analysis of gut microbiota and metabolites in rats with irritable bowel syndrome. Front Cellular Infect Microbiol. 2019;9:178-178.
Kwiecien NW, Bailey DJ, Rush MJ, et al. High-resolution filtering for improved small molecule identification via GC/MS. Anal Chem. 2015;87:8328-8335.
Martin FP, Wang Y, Sprenger N, et al. Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol. 2008;4:157.
Worley B, Powers R. Multivariate analysis in metabolomics. Curr Metabolom. 2013;1:92-107.
Shankar V, Reo NV, Paliy O. Simultaneous fecal microbial and metabolite profiling enables accurate classification of pediatric irritable bowel syndrome. Microbiome. 2015;3:73.
Aggio RB, White P, Jayasena H, de Lacy CB, Ratcliffe NM, Probert CS. Irritable bowel syndrome and active inflammatory bowel disease diagnosed by faecal gas analysis. Aliment Pharmacol Ther. 2017;45:82-90.
Rossi M, Aggio R, Staudacher HM, et al. Volatile organic compounds in feces associate with response to dietary intervention in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2018;16(3):385-391.e1.
van den Berg RA, Hoefsloot HCJ, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genom. 2006;7:142-142.
Yang J, Zhao X, Lu X, Lin X, Xu G. A data preprocessing strategy for metabolomics to reduce the mask effect in data analysis. Frontiers in molecular biosciences. 2015;2:4-4.
Umetrics. SIMCA-P and Multivariate Analysis FAQ. Version 1.01. 26 September http://umetrics.com/sites/default/files/kb/multivariate_faq.pdf.
Worley B, Powers R. PCA as a practical indicator of OPLS-DA model reliability. Current Metabolom. 2016;4:97-103.
Galindo-Prieto B, Eriksson L, Trygg J. Variable influence on projection (VIP) for orthogonal projections to latent structures (OPLS). J Chemometrics. 2014;28:623-632.
Corsetti M, Van Oudenhove L, Tack J. The quest for biomarkers in IBS-where should it lead us? Neurogastroenterol Motil. 2014;26:1669-1676.
Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2009;22:512-519, e114-515.
Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2005;3:349-357.
Bosch S, van Gaal N, Zuurbier RP, et al. Differentiation between pediatric irritable bowel syndrome and inflammatory bowel disease based on fecal scent: proof of principle study. Inflamm Bowel Dis. 2018;24:2468-2475.
Gecse K, Roka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut. 2008;57:591-599.
Annahazi A, Gecse K, Dabek M, et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain. 2009;144:209-217.
Annahazi A, Ferrier L, Bezirard V, et al. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol. 2013;108:1322-1331.
Arasaradnam RP, Westenbrink E, McFarlane MJ, et al. Differentiating coeliac disease from irritable bowel syndrome by urinary volatile organic compound analysis-a pilot study. PLoS ONE. 2014;9:e107312.
Jeffery IB, Das A, O’Herlihy E, et al. Differences in fecal microbiomes and metabolomes of people with vs without irritable bowel syndrome and bile acid malabsorption. Gastroenterology. 2020;158(4):1016-1028.e8.
Simrén M. Diet as a therapy for irritable bowel syndrome: progress at last. Gastroenterology. 2014;146:10-12.
McKenzie YA, Bowyer RK, Leach H, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29:549-575.
Broadhurst D, Goodacre R, Reinke SN, et al. Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics. 2018;14:72.
Shimbori C, De Palma G, Reed DE, et al. 916 - Gut microbiota-diet interactions in a humanized mouse model of IBS: the role of intestinal mast cells. Gastroenterology. 2018;154:S-182.